|
JPH08768B2
(ja)
|
1989-08-24 |
1996-01-10 |
武田薬品工業株式会社 |
神経成長因子分泌誘導剤
|
|
US6232060B1
(en)
|
1996-01-19 |
2001-05-15 |
Galileo Laboratories, Inc. |
Assay system for anti-stress agents
|
|
US5801159A
(en)
|
1996-02-23 |
1998-09-01 |
Galileo Laboratories, Inc. |
Method and composition for inhibiting cellular irreversible changes due to stress
|
|
CA2252519A1
(en)
|
1996-07-11 |
1998-01-22 |
Keisuke Hirai |
Use of idebenone and analogues against beta amyloid induced cytotoxicity
|
|
CN1302287A
(zh)
|
1998-05-22 |
2001-07-04 |
盐野义生物研究公司 |
生物还原性细胞毒试剂
|
|
US7034054B2
(en)
|
2000-12-15 |
2006-04-25 |
Galileo Pharmaceuticals, Inc. |
Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
|
|
US6608196B2
(en)
|
2001-05-03 |
2003-08-19 |
Galileo Pharmaceuticals, Inc. |
Process for solid supported synthesis of pyruvate-derived compounds
|
|
US6667330B2
(en)
|
2002-01-31 |
2003-12-23 |
Galileo Pharmaceuticals, Inc. |
Furanone derivatives
|
|
US6653346B1
(en)
|
2002-02-07 |
2003-11-25 |
Galileo Pharmaceuticals, Inc. |
Cytoprotective benzofuran derivatives
|
|
EP1378753B1
(en)
|
2002-07-01 |
2006-05-31 |
Santhera Pharmaceuticals (Schweiz) GmbH |
A screening method and compounds for treating Friedreich Ataxia
|
|
AU2003287250B9
(en)
|
2002-10-30 |
2010-01-28 |
Ptc Therapeutics, Inc. |
Identifying therapeutic compounds based on their physical-chemical properties
|
|
WO2005033093A1
(en)
|
2003-09-19 |
2005-04-14 |
Galileo Pharmaceuticals, Inc. |
7,8-bicycloalkyl-chroman derivatives
|
|
US7393662B2
(en)
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
|
ES2619303T3
(es)
|
2005-06-01 |
2017-06-26 |
Edison Pharmaceuticals, Inc. |
Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
|
|
SI1933821T1
(sl)
*
|
2005-09-15 |
2020-11-30 |
Ptc Therapeutics, Inc. |
Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev
|
|
WO2007095631A2
(en)
|
2006-02-15 |
2007-08-23 |
The Regents Of The University Of California |
New drug delivery system for crossing the blood brain barrier
|
|
WO2007100652A2
(en)
|
2006-02-22 |
2007-09-07 |
Edison Pharmaceuticals, Inc. |
Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
|
|
WO2008086025A2
(en)
|
2007-01-10 |
2008-07-17 |
Edison Pharmaceuticals, Inc. |
Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
|
|
EA038941B1
(ru)
|
2007-11-06 |
2021-11-12 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
|
|
EP2242506A4
(en)
|
2008-01-07 |
2011-12-28 |
Janssen Biotech Inc |
METHOD FOR THE TREATMENT OF ERYTHROPOIETIN HYPORESPONSE ANIMALS
|
|
US8952071B2
(en)
|
2008-01-08 |
2015-02-10 |
Edison Pharmaceuticals, Inc. |
(Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
|
|
EP2262519A4
(en)
|
2008-03-05 |
2011-03-23 |
Edison Pharmaceuticals Inc |
TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS
|
|
WO2009111576A2
(en)
|
2008-03-05 |
2009-09-11 |
Edison Pharmaceuticals, Inc. |
2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
|
|
US20090291092A1
(en)
|
2008-05-22 |
2009-11-26 |
Miller Guy M |
Treatment of mitochondrial diseases with an erythropoietin mimetic
|
|
JP5798481B2
(ja)
|
2008-06-25 |
2015-10-21 |
エジソン ファーマシューティカルズ， インコーポレイテッド |
酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体
|
|
WO2010005989A1
(en)
|
2008-07-09 |
2010-01-14 |
Edison Pharmaceuticals, Inc. |
Dermatological compositions with anti-aging and skin even-toning properties
|
|
WO2010014758A1
(en)
|
2008-07-30 |
2010-02-04 |
Edison Pharmaceuticals, Inc. |
Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress
|
|
US20100029784A1
(en)
|
2008-07-30 |
2010-02-04 |
Hinman Andrew W |
Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
|
|
MX363223B
(es)
*
|
2008-09-10 |
2019-03-15 |
Bioelectron Tech Corp |
Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
|
|
EP2362726B1
(en)
|
2008-10-14 |
2018-08-08 |
Bioelectron Technology Corporation |
Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
|
|
ES2553557T3
(es)
|
2008-10-28 |
2015-12-10 |
Edison Pharmaceuticals, Inc. |
Proceso para la producción de alfa-tocotrienol y derivados
|
|
US20120136048A1
(en)
|
2009-04-28 |
2012-05-31 |
Miller Guy M |
Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
|
|
EA201101576A1
(ru)
|
2009-04-28 |
2012-04-30 |
Эдисон Фармасьютикалз, Инк. |
Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
|
|
EP2445519A4
(en)
|
2009-06-25 |
2012-12-26 |
Ampere Life Sciences Inc |
TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS USING TOCOTRIENOLS OR TOCOTRIENOLS ENRICHED EXTRACTS
|
|
NO2470168T3
(https=)
|
2009-08-26 |
2018-06-30 |
|
|
|
US20110172312A1
(en)
|
2009-12-31 |
2011-07-14 |
Miller Guy M |
Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
|
|
BR112012022634A2
(pt)
|
2010-03-09 |
2019-09-24 |
Edison Pharmaceuticals Inc |
síntese de derivados de alto-tocoferolquinona e métodos de utilização dos mesmos
|
|
WO2011113018A1
(en)
|
2010-03-12 |
2011-09-15 |
Ampere Life Sciences, Inc. |
Measurement and control of biological time
|
|
CA2795726A1
(en)
|
2010-04-06 |
2011-10-13 |
Edison Pharmaceuticals, Inc. |
Treatment of ataxia telangiectasia
|
|
JP5902673B2
(ja)
|
2010-04-27 |
2016-04-13 |
エジソン ファーマシューティカルズ， インコーポレイテッド |
眼疾患の処置のためのキノンの製剤
|
|
US20120101169A1
(en)
|
2010-07-14 |
2012-04-26 |
Penwest Pharmaceuticals Co. |
Methods of providing anticoagulation effects in subjects
|
|
SG187744A1
(en)
|
2010-08-06 |
2013-03-28 |
Edison Pharmaceuticals Inc |
Treatment of mitochondrial diseases with naphthoquinones
|
|
US20120295985A1
(en)
|
2010-11-19 |
2012-11-22 |
Miller Guy M |
Methods for improving blood glucose control
|
|
WO2012154613A1
(en)
|
2011-05-06 |
2012-11-15 |
Edison Pharmaceuticals, Inc. |
Improved process for the preparation of d-alpha-tocotrienol from natural extracts
|
|
WO2012170773A1
(en)
*
|
2011-06-08 |
2012-12-13 |
Edison Pharmaceuticals, Inc. |
Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
|
|
WO2012174286A1
(en)
|
2011-06-14 |
2012-12-20 |
Edison Pharmaceuticals, Inc. |
Catechol derivatives for treatment of oxidative stress diseases
|
|
ES2795798T3
(es)
|
2011-07-06 |
2020-11-24 |
Ptc Therapeutics Inc |
Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas
|
|
WO2013006736A1
(en)
|
2011-07-06 |
2013-01-10 |
Edison Pharmaceuticals, Inc |
Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
|
|
EP2734512B1
(en)
|
2011-07-19 |
2019-11-20 |
Bioelectron Technology Corporation |
Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
|
|
CA2883882A1
(en)
|
2012-09-07 |
2014-03-13 |
Ptc Therapeutics, Inc. |
Benzoquinone derivatives for treating oxidative stress disorders
|
|
CN105142603B
(zh)
|
2013-03-08 |
2018-10-19 |
荷兰联合利华有限公司 |
用于皮肤病用途的间苯二酚化合物
|
|
US9296712B2
(en)
|
2013-03-15 |
2016-03-29 |
Edison Pharmaceuticals, Inc. |
Resorufin derivatives for treatment of oxidative stress disorders
|
|
US20140275045A1
(en)
|
2013-03-15 |
2014-09-18 |
Edison Pharmaceuticals, Inc. |
Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
|
|
US10189830B2
(en)
|
2013-03-15 |
2019-01-29 |
Bioelectron Technology Corporation |
Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
|
|
EP3004071A1
(en)
|
2013-05-31 |
2016-04-13 |
Edison Pharmaceuticals, Inc. |
Carboxylic acid derivatives for treatment of oxidative stress disorders
|
|
WO2015183963A2
(en)
|
2014-05-28 |
2015-12-03 |
Stealth Peptides International, Inc. |
Therapeutic compositions including redox-active parabenzoquinones and uses thereof
|
|
DK3233786T3
(da)
|
2014-12-16 |
2022-05-09 |
Ptc Therapeutics Inc |
Polymorfe og amorfe former af (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6- dioxocyclohexa-1,4-dienyl)butanamid
|
|
JP2018502127A
(ja)
|
2015-01-12 |
2018-01-25 |
バイオエレクトロン テクノロジー コーポレイション |
放射線被曝に対する防護のためのキノン
|
|
WO2017106786A1
(en)
|
2015-12-16 |
2017-06-22 |
Bioelectron Technology Corporation |
Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
|
|
US10703701B2
(en)
|
2015-12-17 |
2020-07-07 |
Ptc Therapeutics, Inc. |
Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
|
|
CA3011293A1
(en)
|
2016-01-12 |
2017-07-20 |
Ptc Therapeutics, Inc. |
Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels
|
|
WO2017123823A1
(en)
|
2016-01-12 |
2017-07-20 |
Bioelectron Technology Corporation |
Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors
|
|
WO2018081644A1
(en)
|
2016-10-28 |
2018-05-03 |
Bioelectron Technology Corporation |
Methods of analyzing p-hydroquinone levels and ratios
|
|
JP2018083799A
(ja)
|
2016-11-15 |
2018-05-31 |
バイオエレクトロン テクノロジー コーポレイション |
２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
|
|
WO2018129411A1
(en)
|
2017-01-06 |
2018-07-12 |
Bioelectron Technology Corporation |
Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders
|
|
US20180333389A1
(en)
|
2017-04-14 |
2018-11-22 |
Bioelectron Technology Corporation |
Vitamin e compositions and methods of use therefor
|
|
WO2018191732A1
(en)
*
|
2017-04-14 |
2018-10-18 |
Bioelectron Technology Corporation |
Methods and compositions for treatment of inflammation and oxidative stress
|
|
TN2021000075A1
(en)
|
2018-10-17 |
2023-01-05 |
Ptc Therapeutics Inc |
2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
|
|
US20230002324A1
(en)
|
2019-06-13 |
2023-01-05 |
Ptc Therapeutics, Inc. |
Naphthoquinone derivatives for treatment of oxidative stress disorders
|
|
WO2021077034A1
(en)
|
2019-10-18 |
2021-04-22 |
Ptc Therapeutics, Inc. |
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders
|